Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.
In this study, Ecker et al. analyze a national cohort of patients with select high-risk sarcoma who underwent curative-intent resection and evaluated the relationship between regional lymph node identification and survival.
Ecker BL et al. Ann Surg Oncol 2017; 24: 425–433. doi:10.1245/s10434-016-5641-1
In this retrospective study, Al Sannaa et al. examine their institutional experience with sarcomas metastatic to the brain, including histological subtypes, clinical presentation, pathological features, and clinical outcomes.
Al Sannaa G et al. Ann Surg Oncol 2016; 23(Suppl 5): 962–967. doi:10.1245/s10434-016-5559-7